As she was interviewing for the director’s job at the George Washington Cancer Center, Julie E. Bauman was asked what her biggest fear would be.
Cancer organizations and pharmaceutical companies have formed a coalition that seeks to develop licensing agreements to improve access to essential cancer drugs in low- and lower-middle income countries (LLMICs).
When Judy Orem learned of her chronic myeloid leukemia diagnosis in 1995, she chose interferon over a treatment that seemed more risky—a bone marrow transplant.
Fox Chase Cancer Center used to be a place where Nobel laureates toiled. Now, people who love the place—and in oncology, many people do—are hoping that Jonathan Chernoff, Fox Chase’s new director, will restore vitality to the venerable Philadelphia-based cancer center.
FDA is asking sponsors of all investigational medical products to focus on including diverse patients throughout the clinical development process.
Ukrainian refugees and displaced persons with cancer are fighting a double war for survival—which is why aid networks and providers must prioritize psychosocial oncology, said Csaba Dégi, executive secretary of the International Psycho-Oncology Society.
Why is the April 21 ODAC different from all the other ODACs? At all other ODACs, a commercial sponsor gets to make a case. On April 21, only FDA’s voice will be heard.
More than 850 children with cancer have been evacuated or are in the process of evacuation from Ukraine, 45 days after a collaboration of international organizations began transporting pediatric cancer patients out of the country.
On March 7, or 11 days into Russia invasion, Mike Morrissey, chief executive of the European Cancer Organisation, approached the society’s board to inquire as to whether they should convene a special network for Ukraine.
After nearly five years in the federal government—at both NCI and FDA—Ned Sharpless is stepping down from his position as NCI director.
